WOMEN HEALTH DIAGNOSTICS MARKET IS PROSPERING OWING TO THE RISING BURDEN OF INFECTIOUS DISEASES AMONGST WOMEN ALL OVER THE WORLD

The global Women Health Diagnostics Market is expected to exceed the market valuation of more than US$ XX million by 2027 expanding at a reasonable CAGR of XX% during the forecast period (2021-2027). Women Health Diagnostics is becoming an essential part due to the rising incidents of certain diseases such as menstrual disorders, cancer, osteoporosis, sexual disorders, and autoimmune diseases. The major diseases include cervical cancer, breast cancer, infertility, menopause, and polycystic ovarian syndrome (PCOS). According to the WHO, cervical cancer is the fourth most common cancer in women. Approximately 5,70, 000 women were diagnosed with cervical cancer worldwide and about 3,11, 000 women died from the disease in 2018.

For a detailed analysis of the Women Health Diagnostics, market browse through – https://univdatos.com/report/women-health-diagnostics-market

The demand for Women’s Health Diagnostics is mainly increasing on account of the increasing incidence of chronic and lifestyle disorders, rising awareness regarding various health-related disorders, high prevalence of infectious diseases such as hepatitis and HIV in women all over the world. Moreover, the rising number of diagnostic and imaging centers and the high adoption of POC diagnostic testing also propel market growth. In 2019, Abbott announced its Afinion™ HbA1c Dx assay for use on the Afinion 2 Analyzer, as well as the Afinion AS100 Analyzer. The Afinion HbA1c Dx assay is the first and only rapid point-of-care test cleared by the U.S. Food and Drug Administration (FDA) to aid healthcare professionals in the diagnosis of diabetes and the assessment of patients’ risk of developing the condition.

The rise of the COVID-19 has disrupted the demand for the Women Health Diagnostics Market due to shut down of the border across different countries and limited transportation and rising travel restrictions to contain the coronavirus (COVID-19) outbreak. As per the regulatory authorities, breast cancer patients are at higher risk of COVID-19 infection than healthy adults. Thus, screening, surgical procedures, and diagnostic exams are being delayed and severely restricted at hospitals and breast centers.

For a detailed analysis of the COVID-19 Impact on Women Health Diagnostics browse through – https://univdatos.com/report/women-health-diagnostics-market

Based on Applications, the market is fragmented into Breast Cancer Testing, Infectious Disease Testing, Osteoporosis Testing, Pregnancy and Fertility Testing, and Prenatal Testing. Breast Cancer Testing holds the largest share in 2020 and is expected to register the highest CAGR in the upcoming period owing to increasing breast cancer cases and rising awareness about advanced breast cancer diagnostic techniques. As per Breastcancer.org, women in the U.S., are more prone to breast cancer deaths than those for any other cancer. Around 43,600 women in the U.S. are expected to die in 2021 from breast cancer.

Based on End-user, the market is fragmented into Diagnostics Centers, Hospitals, and Homecare. The home care segment holds the largest share in 2020 and is expected to register the highest CAGR in the upcoming period due to the rising incidents of infectious diseases which has resulted in increased use of self-testing kits. For instance, imaware company started in 2017 with a vision to modernize lab testing installed a Thyroid-Stimulating Hormone (TSH) determining self kit for the detection of underactive or overactive thyroid which otherwise can lead to autoimmune diseases and chronic conditions such as diabetes or heart disease.

Request for Sample of the report browses through – https://univdatos.com/request_form/form/474

For a better understanding of the market adoption of Women Health Diagnostics, the market is analyzed based on its worldwide presence in the countries such as North America (United States, Canada, and the Rest of North America), Europe (Germany, France, Italy, Spain, United Kingdom and Rest of Europe), Asia-Pacific (China, Japan, India, Australia, and Rest of APAC), and Rest of World. North America will dominate the Women Health Diagnostics market on account of the rising prevalence of infectious diseases amongst women, increasing adoption of technologically advanced products, and rising government initiatives. In 2021, Hologic, Inc., a global leader in women’s health, acquired Biotheranostics, Inc., a privately held, commercial-stage company that provides molecular diagnostic tests for breast and metastatic cancers, for approximately $230 million, to strengthen its presence in the women’s health diagnostics market. Some of the major players operating in the market include Abbott Laboratories, Becton, Dickinson, and Company, Biomerieux SA, Carestream Health, Hoffmann-La Roche AG, GE Healthcare, Hologic, Inc., Koninklijke Philips N.V., Mankind Pharma, and Siemens AG. Several M&As along with partnerships have been undertaken by these players to boost their presence in different regions.

Global Women Health Diagnostics Market Segmentation

Market Insight, by Applications

• Breast Cancer Testing
• Infectious Disease Testing
• Osteoporosis Testing
• Pregnancy and Fertility Testing
• Prenatal Testing

Market Insight, by End-user

• Diagnostics Centers
• Hospitals
• Homecare

Market Insight, by Region

• North America
  • United States
  • Canada
  • Rest of North America
• Europe
  • France
  • Germany
  • Italy
  • Spain
  • United Kingdom
  • Rest of Europe
• Asia-Pacific
  • China
  • Japan
  • India
  • Australia
  • Rest of Asia-Pacific
• Rest of World

Top Company Profiles

• Abbott Laboratories
• Becton, Dickinson, and Company
• Biomerieux SA
• Carestream Health
• Hoffmann-La Roche AG
• GE Healthcare
• Hologic, Inc.
• Koninklijke Philips N.V.
• Mankind Pharma
• Siemens AG